1. 100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. (April 2020) Authors: Correll, Christoph U.; Newcomer, John W.; Silverman, Bernard; DiPetrillo, Lauren; Graham, Christine; Jiang, Ying; Du, Yangchun; Simmons, Adam; Hopkinson, Craig; McDonnell, David; Kahn, Rene Journal: CNS spectrums Issue: Volume 25:Number 2(2020) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients with Schizophrenia: The 1 Year ENLIGHTEN-2-Extension. (April 2021) Authors: Kahn, Rene; Silverman, Bernard; DiPetrillo, Lauren; Graham, Christine; Jiang, Ying; Yin, Jiani; Simmons, Adam; Bhupathi, Vasudev; Yu, Bei; Hopkinson, Craig; McDonnell, Davidd Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗